PACIRA BIOSCIENCES, INC. Restructuring Charges
PACIRA BIOSCIENCES, INC. (PCRX) reported Restructuring Charges of $3.67 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-02-26
- PACIRA BIOSCIENCES, INC. restructuring charges for the quarter ending 2025-12-31 was -$54.00K, a 106.68% decline year-over-year.
- PACIRA BIOSCIENCES, INC. restructuring charges for the quarter ending 2025-09-30 was $3.73M, a 212.49% increase year-over-year.
- PACIRA BIOSCIENCES, INC. restructuring charges for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. restructuring charges for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. restructuring charges for fiscal 2025 was $3.67M, a 56.94% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. restructuring charges for fiscal 2024 was $8.53M, a 669.34% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. restructuring charges for fiscal 2023 was $1.11M.
- PACIRA BIOSCIENCES, INC. restructuring charges for fiscal 2022 was $0.00.
| Period end | Restructuring Charges 3 month | Restructuring Charges 3 month as first filed | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | -$54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.67M derived: sum of 2 quarters · filed 2026-02-26 | $3.67M derived: sum of 3 quarters · filed 2026-02-26 | $3.67M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $3.73M 10-Q · filed 2025-11-06 | $3.73M derived: sum of 2 quarters · filed 2025-11-06 | $3.73M 10-Q · filed 2025-11-06 | $4.54M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $808.00K derived: sum of 3 quarters · filed 2026-02-26 | $2.00M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $808.00K derived: sum of 2 quarters · filed 2026-02-26 | $2.00M derived: sum of 3 quarters · filed 2026-02-26 | $3.00M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-12-31 | $808.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.00M derived: sum of 2 quarters · filed 2026-02-26 | $3.00M derived: sum of 3 quarters · filed 2026-02-26 | $8.53M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.19M 10-Q · filed 2025-11-06 | $2.19M derived: sum of 2 quarters · filed 2025-11-06 | $7.72M 10-Q · filed 2025-11-06 | $7.72M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $996.00K 10-Q · filed 2025-08-05 | $6.53M 10-Q · filed 2025-08-05 | $6.53M derived: sum of 3 quarters · filed 2026-02-26 | $6.70M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $5.54M 10-Q · filed 2025-05-08 | $3.30M 10-Q · filed 2024-05-07 | $5.54M derived: sum of 2 quarters · filed 2026-02-26 | $5.71M derived: sum of 3 quarters · filed 2026-02-26 | $6.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $173.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.11M derived: sum of 3 quarters · filed 2026-02-26 | $1.11M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $173.00K 10-Q · filed 2024-11-06 | $1.11M derived: sum of 2 quarters · filed 2024-11-06 | $1.11M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $936.00K 10-Q · filed 2024-07-30 | $936.00K 10-Q · filed 2024-07-30 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 | ||||
| 2020-12-31 | -$38.00K 10-K · filed 2021-03-01 | ||||
| 2019-12-31 | $847.00K 10-K · filed 2021-03-01 | ||||
| 2018-12-31 | $1.56M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |